Literature DB >> 28527102

Studies of Environmental Risk Factors in Amyotrophic Lateral Sclerosis (ALS) and a Phase I Clinical Trial of L-Serine.

Walter G Bradley1, R X Miller2, T D Levine3, E W Stommel4, P A Cox5.   

Abstract

β-N-Methylamino-L-alanine (BMAA) has been linked to Guam ALS/PDC and shown to produce neurodegeneration in vitro and in vivo (Drosophila, mice, rats, primates). BMAA misincorporation into neuroproteins produces protein misfolding and is inhibited by L-serine. Case-control studies in Northern New England indicate that living near to water-bodies with cyanobacterial blooms increases the risk of developing amyotrophic lateral sclerosis (ALS). The distribution of addresses of ALS cases in New Hampshire, Vermont, and Florida was compared to that of controls. Areas of statistically significantly increased numbers of ALS cases were examined for sources of environmental toxins. A phase I trial of oral L-serine was performed in 20 ALS patients (0.5 to 15 g twice daily). Safety and tolerability were assessed by comparing the rate of deterioration with 430 matched placebo controls. The distribution of residential addresses of ALS cases in New England and Florida revealed many areas where the age- and gender-adjusted frequency of ALS was greater than expected (P < 0.01). GIS studies of these "hot spots" in relation to sources of environmental pollutants, like cyanobacterial blooms, Superfund and Brownfield sites, and landfills, are ongoing. In the phase I trial of L-serine, two patients withdrew from because of gastrointestinal side effects. Three patients died during the study, which was about the expected number. The ALSFRS-R in the L-serine-treated patients showed a dose-related decrease in the rate of progression (34% reduction in slope, P = 0.044). The non-random distribution of addresses of ALS patients suggests that residential exposure to environmental pollutants may play an important role in the etiology of ALS. L-Serine in doses up to 15 g twice daily appears to be safe in patients with ALS. Exploratory studies of efficacy suggested that L-serine might slow disease progression. A phase II trial is planned.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; BMAA; Cyanobacteria; Environmental epidemiology; L-Serine; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28527102     DOI: 10.1007/s12640-017-9741-x

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  64 in total

1.  Spatial clustering of amyotrophic lateral sclerosis in Finland at place of birth and place of death.

Authors:  C E Sabel; P J Boyle; M Löytönen; A C Gatrell; M Jokelainen; R Flowerdew; P Maasilta
Journal:  Am J Epidemiol       Date:  2003-05-15       Impact factor: 4.897

2.  Cyanobacterial Blooms and the Occurrence of the neurotoxin beta-N-methylamino-L-alanine (BMAA) in South Florida Aquatic Food Webs.

Authors:  Larry E Brand; John Pablo; Angela Compton; Neil Hammerschlag; Deborah C Mash
Journal:  Harmful Algae       Date:  2010-09-01       Impact factor: 4.273

3.  ALSUntangled 38: L-serine.

Authors: 
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-11-29       Impact factor: 4.092

4.  Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1.

Authors:  Kevin Garofalo; Anke Penno; Brian P Schmidt; Ho-Joon Lee; Matthew P Frosch; Arnold von Eckardstein; Robert H Brown; Thorsten Hornemann; Florian S Eichler
Journal:  J Clin Invest       Date:  2011-12       Impact factor: 14.808

5.  Environmental and Occupational Exposures and Amyotrophic Lateral Sclerosis in New England.

Authors:  Angeline S Andrew; Tracie A Caller; Rup Tandan; Eric J Duell; Patricia L Henegan; Nicholas C Field; Walter G Bradley; Elijah W Stommel
Journal:  Neurodegener Dis       Date:  2017-01-26       Impact factor: 2.977

6.  Exposure to hazardous air pollutants and the risk of amyotrophic lateral sclerosis.

Authors:  Angela M Malek; Aaron Barchowsky; Robert Bowser; Terry Heiman-Patterson; David Lacomis; Sandeep Rana; Evelyn O Talbott
Journal:  Environ Pollut       Date:  2014-12-23       Impact factor: 8.071

7.  Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam.

Authors:  S J Murch; P A Cox; S A Banack; J C Steele; O W Sacks
Journal:  Acta Neurol Scand       Date:  2004-10       Impact factor: 3.209

Review 8.  Recreational and occupational field exposure to freshwater cyanobacteria--a review of anecdotal and case reports, epidemiological studies and the challenges for epidemiologic assessment.

Authors:  Ian Stewart; Penelope M Webb; Philip J Schluter; Glen R Shaw
Journal:  Environ Health       Date:  2006-03-24       Impact factor: 5.984

9.  Mapping amyotrophic lateral sclerosis lake risk factors across northern New England.

Authors:  Nathan Torbick; Sarah Hession; Elijah Stommel; Tracie Caller
Journal:  Int J Health Geogr       Date:  2014-01-02       Impact factor: 3.918

10.  Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.

Authors:  Ammar Al-Chalabi; Andrea Calvo; Adriano Chio; Shuna Colville; Cathy M Ellis; Orla Hardiman; Mark Heverin; Robin S Howard; Mark H B Huisman; Noa Keren; P Nigel Leigh; Letizia Mazzini; Gabriele Mora; Richard W Orrell; James Rooney; Kirsten M Scott; William J Scotton; Meinie Seelen; Christopher E Shaw; Katie S Sidle; Robert Swingler; Miho Tsuda; Jan H Veldink; Anne E Visser; Leonard H van den Berg; Neil Pearce
Journal:  Lancet Neurol       Date:  2014-10-07       Impact factor: 44.182

View more
  7 in total

1.  Metabolic profiling of zebrafish (Danio rerio) embryos by NMR spectroscopy reveals multifaceted toxicity of β-methylamino-L-alanine (BMAA).

Authors:  Upasana Roy; Laura Conklin; Jürgen Schiller; Jörg Matysik; John P Berry; A Alia
Journal:  Sci Rep       Date:  2017-12-11       Impact factor: 4.379

2.  Human Scalp Hair as an Indicator of Exposure to the Environmental Toxin β-N-Methylamino-l-alanine.

Authors:  Simoné Downing; Laura Louise Scott; Nadezda Zguna; Timothy Grant Downing
Journal:  Toxins (Basel)       Date:  2017-12-27       Impact factor: 4.546

3.  Angiopoietin-1 and ανβ3 integrin peptide promote the therapeutic effects of L-serine in an amyotrophic lateral sclerosis/Parkinsonism dementia complex model.

Authors:  Hua-Ying Cai; Ke-Wei Tian; Yuan-Yuan Zhang; Hong Jiang; Shu Han
Journal:  Aging (Albany NY)       Date:  2018-11-25       Impact factor: 5.682

4.  l-Serine and EPA Relieve Chronic Low-Back and Knee Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Ikuko Sasahara; Akiko Yamamoto; Masamichi Takeshita; Yasuyo Suga; Katsuya Suzuki; Natsumi Nishikata; Michihiro Takada; Masaki Hashimoto; Tomoyuki Mine; Yasuo Kobuna; Kenji Nagao
Journal:  J Nutr       Date:  2020-09-01       Impact factor: 4.798

5.  Population Pharmacokinetic Model of AST-001, L-Isomer of Serine, Combining Endogenous Production and Exogenous Administration in Healthy Subjects.

Authors:  Soyoung Lee; Su-Kyeong Hwang; Hee-Sook Nam; Jung-Sook Cho; Jae-Yong Chung
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

Review 6.  The effects of diet and sex in amyotrophic lateral sclerosis.

Authors:  J A Pape; J H Grose
Journal:  Rev Neurol (Paris)       Date:  2020-03-05       Impact factor: 2.607

7.  Risk factors for amyotrophic lateral sclerosis: A regional United States case-control study.

Authors:  Angeline S Andrew; Walter G Bradley; Daniel Peipert; Tanya Butt; Kwadwo Amoako; Erik P Pioro; Rup Tandan; John Novak; Adam Quick; K Doug Pugar; Komal Sawlani; Bashar Katirji; Todd A Hayes; Pamela Cazzolli; Jiang Gui; Paul Mehta; D Kevin Horton; Elijah W Stommel
Journal:  Muscle Nerve       Date:  2020-10-18       Impact factor: 3.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.